AstraZeneca Vaccine 'Protects Against Severe Disease, Death'

The Malawi government has announced that it has decided to go ahead with acquiring the Oxford-AstraZeneca Covid-19 vaccine, despite concerns about its efficacy. Alarm bells went off In South Africa, when clinical trials at the University of Witwatersrand in Johannesburg, concluded that the AstraZeneca vaccine provided only "minimal" protection against mild to moderate Covid-19 symptoms caused by the 501.V2 variant. South Africa, Africa's hardest-hit nation, was due to start its vaccination campaign with a million AstraZeneca doses but halted the plans, and may instead switch to a different vaccine. Meanwhile, the World Health Organization has warned against dismissing the vaccine, insisting it was still a vital tool in the global fight against the novel coronavirus pandemic.

InFocus

Africa needs timely access to safe and effective Covid-19 vaccines (file photo).

AllAfrica publishes around 800 reports a day from more than 100 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.

X